European Commission approves Tradjenta (Eli Lilly/Boehringer) for treatment with insulin for patients with Type 2 Diabetes - 29-Oct-2012

Boehringer Ingelheim and Eli Lilly and Company announced that the European Commission has approved an expanded therapeutic indication for the DPP-4 inhibitor Trajenta (linagliptin) to include use in combination with insulin in adults with Type 2 Diabetes. The approval means linagliptin is now indicated for use in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Related News

Related Diabetes and Endocrinology Information

Related Diabetes and Endocrinology Drugs

Back to top

Latest News

10 May 2015
23 May 2013
22 May 2013